Cell Medica doses first neuroblastoma patient with NK cell therapy

Cell Medica Ltd. (London, U.K.) dosed the first patient in the open-label, U.S. Phase I GINAKIT2 trial of CMD-501 to treat relapsed or refractory pediatric neuroblastoma, which the company said marks the first use of an engineered NK cell therapy in humans. CMD-501 is an autologous CAR therapy targeting ganglioside GD2 (GD2) that uses IL-15-expressing NK T cells...